Skip to Content

Posts tagged with "Drug Development"

  • Business and Markets

    Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old generic steroid to the US market. They did no new registrational studies in the clinic, in case you’re wondering. There was a drug-drug interaction study, ADME work, that sort of thing… Read More
  • Academia (vs. Industry)

    A Call For Academic Drug Companies

    An editorial in Cell asks “How Much Longer Will We Put Up With $100,000 Cancer Drugs?” I’m of two minds on questions like that. OK, three minds. The immediate impulse, not an honorable one, is to respond with pure snark, which is always tempting, in the vein of “If you can keep your company going… Read More
  • Business and Markets

    The Hollywood Analogy

    Yesterday’s drug-research-is-hard screed brought a lot of responses, and I wanted to address some particular points that came up. On Twitter, Alex Tabarrok of Marginal Revolution advanced the Hollywood Analogy. I’ve used this one myself; it leads off a talk that I put together a few years ago. The model for a movie studio is… Read More
  • Clinical Trials

    I Do Hate To Tell You This, But. . .

    The timing of this report from the FDA is surely no accident, but it’s always a good time to think about this: the great majority of all drugs that enter clinical trials fail. They fail because they don’t do anyone any good, or because what good they might do is outweighed by some serious and… Read More
  • Chemical Biology

    Curcumin Will Waste Your Time

    I really enjoyed reading this article in J. Med. Chem. on curcumin. (Update: here’s the take over at Practical Fragments). That’s a well-known natural product, found in large quantities in turmeric root (which is where most of the yellow color comes from). It has, over the years, been a hit in many, many assays, and… Read More
  • Alzheimer's Disease

    Vivek Ramaswamy’s Plans

    I last wrote about Vivek Ramaswamy in the context of his first company (Axovant). That one went public on the hopes for a retread Alzheimer’s drug to work out in Phase III, and if that sounds a little iffy to you, then join a fairly large club. Alzheimer’s is truly the approach-avoidance conflict writ large: from… Read More
  • Business and Markets

    Not Fun Reading

    These numbers from Deloitte are not very reassuring. They do an annual survey of spending and returns on investment in the drug industry, and this year’s estimated return on R&D is down to 3.7%, which looks like the lowest yet. Back in 2009, another vast consulting house (McKinsey) estimated that returns were around 7.5% during… Read More
  • Cardiovascular Disease

    The Long Saga of Apo-A1 Milano

    It’s been six years since I titled a post “Remember Apo-A1 Milano?” If you go back even further, I wrote about the topic on this blog back in 2003 (!); scroll down to the November 11 post on that page. You can see from that one that the saga goes well back into the 1990s, but… Read More
  • Clinical Trials

    A Quiet And Sudden Exit for Amiselimod

    Here’s an example of a common behavior in this industry – and to be fair, in many others as well. Big deals are celebrated and press-released at the outset, but if things don’t work out, they end very quietly – as quietly as possible. Sometimes that’s not very possible at all, because a big Phase… Read More
  • Business and Markets

    Productivity Over the Years

    The last couple of years have been very good for the number of drug approvals, reversing a rather worrying trend. But are these data points themselves enough to qualify as a reversal? That’s what John Carroll is asking here, pointing out that even the traditional end-of-the-year flurry of approvals doesn’t look likely to rescue the num… Read More
...345...